AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31767518 — intervention group
Group type: COMPARATOR
Intervention: Alirocumab 150 mg and placebo.
Number of subjects: 23
Study 29130954 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (≤15 mg/day)
Number of subjects: 81
Study 29130954 — intervention group
Group type: COMPARATOR
Intervention: Increased furosemide (≤40 mg/day)
Number of subjects: 81
Study 26401089 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-based sequential therapy (MBST)
Number of subjects: 284
Study 26401089 — intervention group
Group type: COMPARATOR
Intervention: Hybrid therapy
Number of subjects: 284
Study 23881284 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0
Study 23881284 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 0
Study 21928714 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream of Calendula officinalis extract
Number of subjects: 21
Study 21928714 — intervention group
Group type: COMPARATOR
Intervention: Base cream (control)
Number of subjects: 21
Study 19720909 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 135 mg/m(2) over 24 hours plus Cis 50 mg/m(2) day 2 every 3 weeks (PC)
Number of subjects: 513
Study 19720909 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 30 mg/m(2) days 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (VC)
Number of subjects: 513
Study 19720909 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m(2) day 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (GC)
Number of subjects: 513
Study 19720909 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 0.75 mg/m(2) days 1, 2, and 3 plus Cis 50 mg/m(2) day 1 every 3 weeks (TC)
Number of subjects: 513
Study 17262850 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 943
Study 17262850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 943
Study 15364659 — intervention group
Group type: EXPERIMENTAL
Intervention: Service-learning training program at ADS
Number of subjects: 5
Study 15364659 — intervention group
Group type: COMPARATOR
Intervention: Control group serving at other S-L sites
Number of subjects: 5
Study 11443156 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day pegvisomant
Number of subjects: 7
Study 9875631 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV RNA detection in livers
Number of subjects: 26
Study 9875631 — intervention group
Group type: EXPERIMENTAL
Intervention: HGV RNA detection in livers
Number of subjects: 26
Study 9875631 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV DNA detection in livers
Number of subjects: 26
Study 9875631 — intervention group
Group type: COMPARATOR
Intervention: Detection of HCV RNA and HBV DNA in toxic or autoimmune fulminant hepatic failure
Number of subjects: 26
Study 8018795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GRF (1 micrograms/kg)
Number of subjects: 0
Study 8018795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2730280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate
Number of subjects: 20
Study 2730280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride
Number of subjects: 20
Study 2730280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30129089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 774
Study 30129089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 774
Study 30129089 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 774
Study 30129089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 774
Study 28349250 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 246
Study 28349250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 25424146 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiFix
Number of subjects: 60
Study 25424146 — intervention group
Group type: COMPARATOR
Intervention: Apligraf
Number of subjects: 60
Study 25424146 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 23296629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic stone protein (PSP)
Number of subjects: 137
Study 23296629 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 137
Study 23296629 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 137
Study 23296629 — intervention group
Group type: EXPERIMENTAL
Intervention: soluble human triggering receptor expressed on myeloid cells-1 (sTREM-1)
Number of subjects: 137
Study 23296629 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF)
Number of subjects: 137
Study 23296629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PSP (>9 ng/ml) and PCT (>2 ng/ml)
Number of subjects: 137
Study 21955225 — intervention group
Group type: EXPERIMENTAL
Intervention: T40/A10
Number of subjects: 947
Study 21955225 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/A10
Number of subjects: 947
Study 21955225 — intervention group
Group type: COMPARATOR
Intervention: A10
Number of subjects: 947
Study 19393142 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 0
Study 19393142 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 0
Study 16289171 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective REM sleep deprivation by selective REM sleep awakenings
Number of subjects: 107
Study 16289171 — intervention group
Group type: COMPARATOR
Intervention: Woken during stage 2 NREM sleep in matched frequency
Number of subjects: 107
Study 16289171 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological REM sleep augmentation via REM sleep rebound after selective REM sleep deprivation
Number of subjects: 107
Study 16289171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological REM sleep augmentation by administering an acetylcholinesterase inhibitor
Number of subjects: 107
Study 12888122 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg fludrocortisone p.o.
Number of subjects: 10
Study 12888122 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg aldosterone i.v.
Number of subjects: 10
Study 12888122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11038029 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8689991 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.4, 0.8, and 1 mg bolus injections followed by 1 mg/h infusion for 3 hours)
Number of subjects: 32
Study 8689991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 hours infusion)
Number of subjects: 32
Study 1411891 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed vault technique using absorbable staples
Number of subjects: 102
Study 1411891 — intervention group
Group type: COMPARATOR
Intervention: Open vault technique
Number of subjects: 102
Study 4059478 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress monitoring and intervention program
Number of subjects: 453
Study 4059478 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 453
Study 30551121 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g · kg‐1 BW NaHCO3
Number of subjects: 21
Study 30551121 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g · kg‐1 BW NaHCO3
Number of subjects: 21
Study 30551121 — intervention group
Group type: COMPARATOR
Intervention: Control (0.3 g · kg‐1 BW placebo)
Number of subjects: 21
Study 29097329 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐day zero‐calorie diet with water provided ad libitum
Number of subjects: 11
Study 29097329 — intervention group
Group type: COMPARATOR
Intervention: 2‐day usual diet
Number of subjects: 11
Study 26780639 — intervention group
Group type: EXPERIMENTAL
Intervention: Framed Task (FT) reporting only lung nodule/s
Number of subjects: 10
Study 26780639 — intervention group
Group type: COMPARATOR
Intervention: Unframed Task (UFT) to report any abnormality
Number of subjects: 10
Study 22578920 — intervention group
Group type: EXPERIMENTAL
Intervention: End-fire transrectal ultrasound probe
Number of subjects: 297
Study 22578920 — intervention group
Group type: COMPARATOR
Intervention: Side-fire transrectal ultrasound probe
Number of subjects: 297
Study 20955445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 94
Study 20955445 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller myotomy with fundoplication (LHM+Fp)
Number of subjects: 94
Study 20955445 — intervention group
Group type: COMPARATOR
Intervention: LHM+Fp
Number of subjects: 94
Study 18033807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation/GnRH antagonist co-treatment with single embryo transfer
Number of subjects: 404
Study 18033807 — intervention group
Group type: COMPARATOR
Intervention: Standard stimulation/GnRH agonist long protocol with transfer of two embryos
Number of subjects: 404
Study 16372578 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg three times daily, orally
Number of subjects: 60
Study 16372578 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatment plus TMZ
Number of subjects: 60
Study 16372578 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 60
Study 12523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (two two-hour group sessions followed by one or two individual sessions administered by a nurse and a physiotherapist)
Number of subjects: 78
Study 12523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 78
Study 12523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (5% improvement in FEV1)
Number of subjects: 78
Study 12523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (NNE to make one person symptom free)
Number of subjects: 78
Study 12523089 — intervention group
Group type: COMPARATOR
Intervention: Control group (ordinary outpatient care)
Number of subjects: 78
Study 9607046 — intervention group
Group type: EXPERIMENTAL
Intervention: Triviraten Berna Vaccine
Number of subjects: 0
Study 9607046 — intervention group
Group type: COMPARATOR
Intervention: MMR-Vax
Number of subjects: 0
Study 9607046 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-Vax and Triviraten Berna (reimmunization)
Number of subjects: 0
Study 7895354 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy
Number of subjects: 305
Study 7895354 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 305
Study 2115892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (2-18 mg)
Number of subjects: 33
Study 2115892 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2-15 mg)
Number of subjects: 33
Study 2115892 — intervention group
Group type: COMPARATOR
Intervention: No drugs
Number of subjects: 33
Study 345410 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1,000 mg daily for two months
Number of subjects: 22
Study 345410 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two months
Number of subjects: 22
Study 345410 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole in patients with colonic involvement
Number of subjects: 22
Study 31434605 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 886
Study 31434605 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 886
Study 29394971 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication and weight-bearing exercises
Number of subjects: 274
Study 29394971 — intervention group
Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 274
Study 27723228 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 6000
Study 23954029 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of biomarkers to increase the sample fraction that would develop Alzheimer's disease from 0.5 to 0.8
Number of subjects: 200
Study 23954029 — intervention group
Group type: EXPERIMENTAL
Intervention: Assuming homogeneity of parameter estimates
Number of subjects: 200
Study 22918094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 to 0.75 mg/kg)
Number of subjects: 60
Study 22918094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol
Number of subjects: 60
Study 22918094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triclofos
Number of subjects: 60
Study 22918094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zolpidem
Number of subjects: 60
Study 20063224 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fluid group (lactated ringers at 250 ml per hour)
Number of subjects: 80
Study 20063224 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study 17655695 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) + HBV vaccine (40 mug HBV(vac) after 5 mug/kg GM-CSF injection)
Number of subjects: 102
Study 17655695 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccine (40 mug HBV(vac) intramuscularly)
Number of subjects: 102
Study 16338252 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 232
Study 16338252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 232
Study 16338252 — intervention group
Group type: COMPARATOR
Intervention: Control group (normolipidemic)
Number of subjects: 232
Study 11939915 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1% Fresenius
Number of subjects: 60
Study 11939915 — intervention group
Group type: COMPARATOR
Intervention: Diprivan 1%
Number of subjects: 60
Study 10419609 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotic fluid (EA) at 11+0‐12+6 weeks
Number of subjects: 4107
Study 10419609 — intervention group
Group type: COMPARATOR
Intervention: Mid amniotic fluid (MA) at 15+0‐16+6 weeks
Number of subjects: 4107
Study 8819183 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (25 + 50 + 100 micrograms)
Number of subjects: 13
Study 8819183 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (100 + 200 + 400 micrograms)
Number of subjects: 13
Study 8819183 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (400 mg)
Number of subjects: 13
Study 8819183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2048661 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36
Study 2048661 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 36
Study 2048661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 7295883 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone tablet formulation A (2 mg)
Number of subjects: 9
Study 7295883 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone tablet formulation B (2 mg)
Number of subjects: 9
Study 7295883 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate solution C (2 mg)
Number of subjects: 9
Study 31638946 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual cup arm
Number of subjects: 0
Study 31638946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer arm
Number of subjects: 0
Study 31638946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cups and cash combined intervention arm
Number of subjects: 0
Study 31638946 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 28809995 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 221
Study 28809995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 25583754 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/linagliptin 5 mg
Number of subjects: 642
Study 25583754 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/linagliptin 5 mg
Number of subjects: 642
Study 25583754 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 642
Study 25583754 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 642
Study 25583754 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 642
Study 24886516 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based only
Number of subjects: 179
Study 24886516 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic nurse support (3 sessions in 3 months)
Number of subjects: 179
Study 24886516 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nurse support (7 sessions in 6 months)
Number of subjects: 179
Study 24886516 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 179
Study 22341370 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9-tetrahydrocannabinol
Number of subjects: 17
Study 22341370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 20598270 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with feedback on gender-marked noun phrases
Number of subjects: 0
Study 20598270 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with feedback
Number of subjects: 0
Study 17055561 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based walking intervention (n=102)
Number of subjects: 202
Study 17055561 — intervention group
Group type: COMPARATOR
Intervention: Usual primary health care (Control group, n=100)
Number of subjects: 202
Study 15475599 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing depth at 80% of total lung capacity (TLC)
Number of subjects: 12
Study 15475599 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing depth at 90% of total lung capacity (TLC)
Number of subjects: 12
Study 15475599 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing depth at 100% of total lung capacity (TLC)
Number of subjects: 12
Study 15475599 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breaths of any amplitude
Number of subjects: 12
Study 12384623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 1100
Study 12384623 — intervention group
Group type: COMPARATOR
Intervention: Bare Bx velocity stent
Number of subjects: 1100
Study 10445557 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (5 MU/m2 three times weekly for 6 months)
Number of subjects: 64
Study 10445557 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 64
Study 8695970 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP at the dose of 20 mg F-equivalents + 600 mg calcium/day
Number of subjects: 42
Study 8695970 — intervention group
Group type: COMPARATOR
Intervention: 500 mg/day of oral calcium
Number of subjects: 42
Study 2392980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2392980 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1-selective beta blocker (metoprolol)
Number of subjects: 30
Study 2392980 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1-nonselective beta blocker (propranolol)
Number of subjects: 30
Study 7308268 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine 240 mg
Number of subjects: 8
Study 7308268 — intervention group
Group type: COMPARATOR
Intervention: furosemide 240 mg
Number of subjects: 8
Study 31087185 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol 0.75 μg
Number of subjects: 265
Study 31087185 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol 1.0 μg
Number of subjects: 265
Study 28050642 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (10 mg)
Number of subjects: 210
Study 28050642 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (60 mg)
Number of subjects: 210
Study 28050642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablet)
Number of subjects: 210
Study 25872802 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU VAS at <3 d and placebo at 6 weeks postpartum
Number of subjects: 128
Study 25872802 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo at <3 d and 200,000 IU VAS at 6 weeks postpartum
Number of subjects: 128
Study 25872802 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU VAS, both at <3 d and 6 weeks postpartum
Number of subjects: 128
Study 25872802 — intervention group
Group type: COMPARATOR
Intervention: Placebo, both at <3 d and 6 weeks postpartum
Number of subjects: 128
Study 25872802 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant blood samples at 2 and 4 months of age
Number of subjects: 128
Study 22658571 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic training (AT) with resistance training (RT) and inspiratory muscle training (IMT) (ARIS)
Number of subjects: 27
Study 22658571 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 27
Study 22136279 — intervention group
Group type: EXPERIMENTAL
Intervention: Chungkookjang (CKJ) pills, 35 g per day for 3 months
Number of subjects: 60
Study 22136279 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills, 35 g per day for 3 months
Number of subjects: 60
Study 22136279 — intervention group
Group type: EXPERIMENTAL
Intervention: Chungkookjang (CKJ) pills
Number of subjects: 60
Study 22136279 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 60
Study 18801775 — intervention group
Group type: EXPERIMENTAL
Intervention: Worn shoes
Number of subjects: 24
Study 18801775 — intervention group
Group type: COMPARATOR
Intervention: New shoes
Number of subjects: 24
Study 18801775 — intervention group
Group type: COMPARATOR
Intervention: Different footwear types (air/gel/spring)
Number of subjects: 24
Study 16518360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-based system (Group 1)
Number of subjects: 60
Study 16518360 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound (Group 2)
Number of subjects: 60
Study 16961791 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid condition (L-tryptophan present)
Number of subjects: 73
Study 16961791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion condition (L-tryptophan omitted)
Number of subjects: 73